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Abstract 
 
MicroRNAs (miRs) are small noncoding RNAs that govern many biological processes. They 
frequently acquire a gain or a loss of function in cancer and hence play a causative role in 
the development and progression of neoplasms. They could be used as biomarkers to improve 
our knowledge on diagnosis, prognosis and drug resistance, and to attempt therapeutic 
approaches in several types of cancer including clear cell renal cell carcinoma (ccRCC). ccRCC 
is the most predominant subtype of RCC that accounts for about 90% of all renal cancers. 
Since ccRCC is generally asymptomatic until very late, it is difficult to diagnose early. 
Moreover, in the absence of preventive treatments for metastatic ccRCC after surgical 
resection of the primary cancer, predictive prognostic biomarkers are needed in order to 
achieve appropriate therapies. Herein the role of miRs in the biology of ccRCC and the 
potential applications of these molecules are discussed. Moreover, future applications in the 
diagnostic and prognostic field, as well as their impact on drug response and therapeutic 
targets are also explored. Their use in clinical practice as molecular biomarkers alone, or in 
combination with other biological markers could accelerate progress, help design 
personalized therapies, limit side effects, and improve quality of life of ccRCC patients.  
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Introduction 
 
Renal cell carcinoma (RCC) accounts for 2-
3% of all cancers and is the most common 
kidney malignancy with the highest 
mortality rate of urinary cancers. Lifestyle 
factors including smoking, obesity and 
hypertension are considered etiological risk 
factors for this tumor (1-3). RCC is mainly 
classified into three major subtypes: clear 
cell (ccRCC), papillary (pRCC) and 
chromophobe (chRCC). The ccRCC subtype 
is the most common accounting for 80-90% 
of RCC cases (3). Generally, ccRCC arises 
from the epithelial cells of the proximal 
convoluted renal tubule and is histologically 
characterized by clear cells separated by 
hypervascular thin fibrous septae (4-5). This 
subtype of renal cancer commonly 
metastasizes to the bones, lungs, brain and 
liver through the invasion of the vena cava 
(6). Currently, partial or radical 
nephrectomy is the only curative treatment 
for localized tumors with high quality of life 
outcomes (3). In comparison, for patients 
with metastatic ccRCC, nephrectomy is 
mostly palliative and systemic treatment 
with pharmacological therapy is necessary. 
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Unfortunately, ccRCC is unresponsive to 
traditional chemotherapies, highly resistant 
to radiation, and lacks the hallmark genetic 
features of solid tumors, such as mutations 
in KRAS and TP53 genes (7).  
 
Recent advances in molecular biology have 
led to the identification of a plethora of gene 
mutations associated with the development 
and progression of ccRCC. It is well known 
that the von Hippel-Lindau (VHL) gene, 
localized on chromosome 3p, is frequently 
inactivated either by mutation or 
methylation in over 80% of ccRCC patients. 
The VHL protein complexes with other 
proteins, and functions as an E3 ubiquitin 
ligase. This leads to degradation of the α 
subunit of hypoxia-inducible transcription 
factors (HIF1 and HIF2) via proteasome 
activation (8-9). The loss of function of VHL 
prevents the degradation of HIFα proteins 
resulting in the increased expression of 
angiogenic factors including vascular 
endothelial growth factor (VEGF) and 
platelet-derived growth factor B chain 
(PDGF-B) that contribute to growth and 
expansion of tumor (10). Mutations in 
mammalian target of rapamycin (mTOR), 
TSC1, PIK3CA, and PTEN genes in 
approximately 20% of ccRCC have also been 
observed. These molecular lesions cause an 
aberrant mTORC1 pathway activation that 
could play a relevant role in the neoplastic 
transformation of kidney cells (8). The 
discovery of several altered signaling 
pathways associated with ccRCC has 
opened new opportunities and strategies in 
the treatment of ccRCC, especially the 
targeted inhibition of molecules involved in 
VEGF and mTOR pathways (11-12). 
However, complete remission or long-term 
beneficial responses with tyrosine kinase or 
mTOR inhibitors are rare (12). Moreover, 
these pharmacological approaches are 
expensive and show significant adverse 
effects that worsen the quality of life of 
ccRCC patients. Thus, cost-effective 
predictive biomarkers that are able to 
improve clinical management of ccRCC 
patients are needed. In this regard, an 
attractive solution could be offered by 
microRNAs (miRs) that are involved in the 
development of many cancers. Herein we 
discuss the role of miRs in RCC biology and 
their possible applications as biomarkers for 
ccRCC.  
 
Biogenesis and function of microRNAs 
 
MiRs are short non-coding single stranded 
RNAs of 20-22 nucleotides in length that 
regulate gene expression at the post-
transcriptional level. They act by inhibiting 
the translation of mRNA primarily by pairing 
with the 3′-untranslated region (UTR) of 
their complementary mRNAs (13). MiRs are 
transcribed by RNA polymerase II or RNA 
polymerase III into a long primary nuclear 
miR (primiRNA) that is cleaved to 70-80 bp 
long pre-miRNA by the Drosha/DGCR8 
complex and exported into the cytoplasm via 
exportin-5/RanGTP (14-15). Pre-miRNAs 
are then digested to double-stranded 
mature miRs by the RNAse III Dicer, and 
separated in two strands: the miRNA-guide 
strand and the miRNA-passenger strand. 
The miRNA-guide strand is loaded into the 
RNA-induced silencing complex (RISC) and 
driven to the target mRNA, while the miRNA-
passenger strand is generally degraded. 
MiRNA gene silencing may be performed 
through degradation via complete pairing, 
where the mRNA target is degraded; or 
incomplete pairing, with the inhibition of 
translation or the decay of mRNA into 
cytoplasmic foci termed P bodies (14). MiRs 
regulate several cellular processes such as 
apoptosis, proliferation, hematopoiesis and 
angiogenesis (13). Pertinent to tumors, they 
can act either as pro- or anti-oncogenic 
molecules, thereby having a dual role in 
oncogenesis. They can act either as tumor 
suppressors by targeting oncoproteins or as 
tumor promoters by downregulating the 
expression of tumor suppressor proteins 
(16-17). Moreover, a large number of miRs 
have been identified to regulate cellular 
metabolism that is often altered in tumor 
cells contributing to development and 
progression of cancer (18). 
 
MicroRNAs affect biological processes in 
ccRCC 
 
It is well known that miRs are involved in 
the pathophysiology of a variety of kidney 
diseases including diabetic nephropathy, 
polycystic kidney disease, Wilms tumor and 
kidney cancer (13). This section focuses on 
the role of miRs in kidney cancer with 
emphasis on cell growth, angiogenesis, 
apoptosis and autophagy (Figure 1; Table 
1). 
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Figure 1: Dysregulated microRNAs affecting cell growth, angiogenesis, apoptosis and autophagy in 
kidney cancer. In the sketch, microRNAs targeting genes involved in mTOR (green), VHL/HIF-α (yellow) 
and p53 (red) pathways as well as in autophagic process (orange) are shown. 
 
 
Cell growth and migration 
 
As observed in other tumors, miRs may 
contribute to development of RCC by 
modulating the expression of genes involved 
in this cancer. For example, VHL is targeted 
by miR-106a, miR-92a and miR-21, which 
have been found upregulated in renal 
carcinoma tissues (19-20). Moreover, VHL 
loss of function can activate the expression 
of different miRs including the miR-17-92 
cluster, also known as oncomiR-1. These 
miRs act as oncogenic agents targeting 
PTEN and E2Fs tumor suppressor genes 
(21-22). Furthermore, VHL 
deletion/mutation also causes the 
enhancing of miR-28-5p expression that in 
turn induces the reduction of Mad2 protein 
levels, thereby promoting checkpoint 
weakness and chromosomal instability in 
ccRCC cells and tissues (23). In addition, 
the impaired VHL signaling causes the 
activation of HIF pathway, which leads to 
the upregulation of miR-210 and miR-155 
which have been identified as having 
oncogenic properties in ccRCC (19-20, 24). 
Conversely, hypoxia can lead to the 
downregulation of miRs that target the 
HIF1α transcripts. MiR-20b and miR-199a 
are repressed under conditions of hypoxia 
(25). Furthermore, hypoxia may reduce 
miRs that target VEGF and promote 
angiogenesis (25). Besides VHL gene, miR-
21 may degrade PTEN mRNA leading to the 
activation of Akt and mTOR kinases which 
contribute to growth and migration of 
kidney cancer cells (26). In ACHN and 786-
0 cells, miR-21 induced migration and 
invasion through the modulation of the pro-
apoptotic protein PDCD4 (19, 27). 
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Table 1: MicroRNAs dysregulated in renal cancer 
 
 
 
In addition, it also promoted tumor 
metastasis by negatively regulating the 
tumor suppressor gene tropomyosin-1 (19). 
Other miRs targeting PTEN and mTOR 
MicroRNAs Target genes Expression Role Applications Ref. 
 miR-501-5p, miR-
23b-3p 
TSC1, PTEN, 
MCU 
Up Cell growth, 
metastasis 
Prognosis 2, 28 
miR-21, 106a, 92a VHL, PTEN, 
PDC4 
Up Cell growth, 
migration 
Prognosis 19-20, 26-
27, 52 
miR-210, 155 ISCU1/2, 
TP53INP1  
Up Metastasis, cell 
growth 
Diagnosis/prognosis 20, 24, 44-
45, 49-50 
miR-20b, 199a HIF-α Down Anti-angiogenesis - 25 
17-92 cluster PTEN, E2Fs   Up Cell growth, 
invasion 
Prognosis 20-22, 24 
miR-28-5p Mad2 Up Chromosomal 
instability 
- 23 
miR-192, 194, 215 ZEB2, MDM2, 
TYMS 
Down Cell differentiation Prognosis 29 
miR-584 ROCK1 Down Cell cycle arrest - 30 
miR-135a cMYC Down Cell cycle arrest - 31 
miR-205 SFKs Down Cell cycle arrest, 
apoptosis 
- 32 
miR-708 Survivin, 
ZEB2, BMI1 
Down Apoptosis - 33 
miR-1826 CTNNB1, 
MEK1 
Down Cell cycle arrest, 
apoptosis 
- 34 
miR-30d, 185 MTDH, VEGFA Down Apoptosis - 35-36 
miR-204 LC3B  Down Autophagy - 37-38 
miR-30a BECN1 Down Inhibition of 
autophagy 
- 39 
miR-203, 424 FGF2, PDCD4 Up Cell proliferation Diagnosis 41 
miR-195, 15b Raf-1, CCND1 Up Cell cycle arrest Diagnosis 42 
miR-122-5p HIF1- α 
vimentin 
Up Inhibition of cell 
invasion 
Diagnosis 43 
miR-378, 451 TOB2, BCL2 Up/down Apoptosis, cell 
cycle 
Early diagnosis 46 
miR-1233 BLCAP, TP53 Up Inhibition of 
apoptosis 
Early diagnosis 47 
miR-193a, 362, 
572, 28, 378 
MAPK, NFkB, 
Mad2 
Up/down Cell growth and  
invasion 
Early diagnosis 48 
miR-126 VEGFA, BCL2 Down Cell migration, 
apoptosis 
Prognosis 51-52 
miR-125b E2F3, TP53 Up Cell growth and 
migration 
Prognosis 53 
miR-30c Snail1/slug, 
PTP4A1 
Down Inhibition of cell 
migration 
Prognosis 55 
miR-200c CYP1B1, HO-1 Down Inhibition of cell 
invasion 
Drug response  58-59 
miR-942 BRCA 
pathway 
Up Angiogenesis, 
metastasis 
Drug response 60 
miR-141 ZEB2 Down Cell differentiation Drug response 61 
miR-200 IL-8,  CXCL1 Down Anti-angiogenesis Therapy 63 
miR-99a mTOR Down Cell cycle arrest Therapy 64 
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mRNAs such as miR-501-5p and miR-23b-
3p show oncogenic features in different 
ccRCC cell lines (2, 28). In ccRCC tissue of 
patients that developed distant metastases, 
a significant increase of miR-501-5p 
expression was observed (2). In KJ29 and 
Caki-2 ccRCC cells, miR-501-5p stimulated 
cell proliferation via mTOR-mediated MDM2 
upregulation. MiR-23b-3p was upregulated 
in A-498 and Caki-2 ccRCC cell lines and its 
downregulation induced apoptosis and 
reduced invasion (28). In patients, an 
increased expression correlated with lower 
survival rate (28). 
 
Cell differentiation and apoptosis 
 
The downregulation of miRs targeting 
specific oncogenes may contribute to the 
development and progression of RCC. In this 
regard, miR-192, miR-194 and miR-215 are 
highly expressed in normal kidney, but they 
are significantly downregulated in both 
primary and metastatic ccRCC. These miRs 
target ZEB2, MDM2 and TYMS mRNAs that 
are associated with cancer development and 
metastasis. The restoration of these miRs 
causes a reduction of cell migration and 
invasion in RCC cell lines (29). Moreover, 
miR-584, which is downregulated in ccRCC 
tissues, functions as a tumor suppressor 
miR that inhibits cell motility by the 
negative regulation of ROCK-1 oncogene 
expression (30). Similarly, miR-135a was 
found significantly reduced in renal cancer 
tissues and its restoration in both Caki-2 
and A498 ccRCC cell lines caused cell cycle 
arrest in G0/G1 phase. It also targeted the 
c-MYC oncogene which was upregulated in 
ccRCC tissues (31). Cell cycle arrest may be 
also induced by miR-205 restoration that 
leads to inhibition of Src family kinases 
(SFKs) expression, stimulating apoptosis 
and inhibiting cell proliferation, migration, 
and colony formation in renal cancer cells. 
This miR is significantly suppressed in renal 
cancer cell lines and tumor tissues (32). 
 
Pro-apoptotic miRs are often downregulated 
in ccRCC. For instance, miR-708, which 
exerts pro-apoptotic effects in ccRCC cells 
and tissues by targeting survivin, ZEB2 and 
BMI1 genes that are involved in cell survival, 
adhesion, invasion, and metastasis, has 
been found widely reduced in human RCC 
tissues. The restoration of miR-708 
dramatically increases apoptosis in ccRCC 
cell lines. Moreover, the intra-tumoral 
delivery of this miR stimulates the 
regression of tumors in murine xenograft 
models of human RCC (33). Similarly, miR-
1826 that is significantly downregulated in 
renal cancer tissues acts as tumor 
suppressor agent promoting apoptosis and 
cell cycle arrest by knockdown of  CTNNB1 
(beta-catenin) and MEK1 genes in VHL-
inactivated ccRCC cells (34). The miRs miR-
30d and miR-185 also may function as 
onco-suppressors in ccRCC cells inducing 
apoptosis through the inhibition of the 
oncoprotein metadherin (MTDH) and VEGF 
A (VEGFA) expression (35-36). 
 
Autophagy 
 
Autophagy is an important mechanism that 
plays both pro- and anti-oncogenic roles. In 
kidney cancer, the pro- or anti-oncogenic 
role of autophagy is mediated by two 
different forms of autophagic protein LC3, 
LC3B and C, which are regulated by the VHL 
protein. The expression of LC3B supports 
tumor formation and progression in renal 
cancer cells with VHL loss of function, whilst 
the expression of LC3C shows tumor 
suppressor activity (37). A functional VHL 
protein inhibits LC3B-mediated autophagy 
through the stimulation of miR-204, which 
directly targets LC3B mRNA reducing its 
translation. In ccRCC cells and metastatic 
tissues, most of which are characterized by 
early inactivation of the VHL gene, a 
reduction of miR-204 expression as well as 
an increase of LC3B protein levels have been 
reported.  Thus, in kidney cells, miR-204, in 
a network involving VHL, functions as a 
tumor suppressor miR that inhibits pro-
oncogenic autophagy by targeting LC3B 
mRNA (37-38). The expression of miR-30a 
may also affect autophagy in kidney cancer. 
It acts as an onco-suppressing agent and 
inhibits autophagy by targeting the BECN1 
gene that codes for beclin-1, a protein 
crucial for the formation of the 
autophagosome. This miR is significantly 
reduced in both human RCC tissues and 
cell lines, and its restoration not only causes 
the inhibition of autophagy by the reduction 
of beclin-1 protein but also enhances 
sorafenib-induced cytotoxicity in different 
ccRCC cell lines (39). Autophagy may 
represent an attractive target for the design 
of new therapeutic approaches in chemo-
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resistant metastatic renal cancer by using 
specific drugs for the inhibition of pro-
oncogenic autophagy. However, further 
studies are needed to evaluate the pro- or 
anti-oncogenic role of autophagy in renal 
cancer. 
 
MicroRNAs and their applications in 
ccRCC 
 
In RCC patients after surgical resection no 
effective preventive adjuvant therapy is 
available. The likelihood of relapse or 
metastases in high grade ccRCC is frequent 
(40). Moreover, the lack of specific 
prognostic biomarkers prevents the 
development of specific therapy. Thus, the 
discovery of new biomarkers for prognosis of 
ccRCC could be useful for the clinical 
management of these cancers (2). In this 
regard, miRs that are involved in 
carcinogenesis could be considered as 
predictive biomarkers for kidney cancer. The 
stable nature of these molecules and their 
relative ease of detection and recovery in 
biological fluids make them optimal 
candidates as molecular biomarkers. In 
particular, they could be used as 
diagnostic/prognostic tools and for the 
design of new therapeutic strategies (Figure 
2). 
 
MicroRNAs for the identification of kidney 
cancer subtypes 
 
Immunohistochemical markers do not allow 
the accurate identification of tumor 
subtypes, especially in the setting of 
uncommon morphology and small biopsies. 
However, miRs that are well established as 
regulators of tumorigenesis could be utilized 
as potential biomarkers alone or in 
combination with current markers in order 
to improve the classification of kidney 
cancer. In this regard, miR-424 and miR-
203 that are overexpressed in ccRCC but 
not in pRCC could be used to distinguish 
ccRCC from pRCC (41). Also miR-195 and 
miR15b are upregulated in ccRCC 
compared with pRCC, chRCC and 
oncocytoma (42). The expression of miR-
126-3p is higher in ccRCC than in pRCC 
tissues, while miR-122-5p, which is highly 
expressed in liver, was specifically 
expressed in ccRCC but not in the other 
subtypes of RCC (43). The differential 
expression of 24 miRs in different kidney 
cancer subtypes was reported to distinguish 
all 4 common subtypes of kidney tumors 
with an overall accuracy of 95% (43). 
Therefore, these miRs could be considered 
as diagnostic biomarkers in order to 
improve the classification of renal cell 
carcinoma.  
 
Circulating microRNAs for early diagnosis of 
ccRCC 
 
Circulating miRs could serve as non-
invasive biomarkers for the early diagnosis 
of kidney carcinoma. In this regard, miR-
210 that is strongly upregulated in ccRCC 
tissue, is also abundantly found in the 
serum of ccRCC patients compared with 
healthy controls. These findings suggest 
that miR-210 could be used as biomarker 
for early diagnosis of ccRCC (19,44-45). 
Other studies report that levels of miR-378 
are increased, while those of miR-451 are 
decreased in serum of RCC patients 
compared with healthy controls. The 
detection of miR-378 and miR-451 in serum 
allows the identification of patients with 
RCC with a sensitivity of 81% and a 
specificity of 83%, making the combination 
of these miRs a possible early diagnostic 
biomarker for RCC (46). Also the circulating 
miR-1233 could also serve as a potential 
diagnostic biomarker for this cancer (47). 
Recently, it has been reported that serum 
levels of miR-193a-3p, miR-362 and miR-
572 are significantly increased whereas 
those of miR-28-5p and miR-378 are 
decreased in patients with RCC compared 
with the healthy controls. The combined use 
of these 5 miRs could serve as a biomarker 
panel for the identification of early stage 
renal cancer with a sensitivity of 80% and a 
specificity of 71% (48). However, further 
studies are needed to validate candidate 
circulating miRs as biomarkers for early 
diagnosis of renal cancer by using large 
multicentre-cohorts of patients. 
 
MicroRNAs for ccRCC prognosis 
 
Apart from early diagnosis, miRs could also 
serve as prognostic markers. In this regard, 
a high level of miR-210 was associated with 
a good clinico-pathological outcome in 
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Figure 2: Flow chart of possible future management of RCC patients by using microRNAs. MicroRNAs 
with diagnostic, prognostic and therapeutic properties along with drug response are indicated. 
Prognostic miRs should allow the identification of ccRCC patients that need specific therapeutic 
treatments from those which do not need pharmacological therapy. 
 
 
ccRCC patients (49), however, other studies 
have associated a high miR-210 with a 
higher chance of disease recurrence and 
shorter overall survival (24, 50). This 
discrepancy suggests that further studies to 
define the role of miR-210 in ccRCC are 
needed. Lower levels of miR-215 (29) and 
miR-126 (51) are associated with a worse 
outcome in RCC patient and a higher 
expression of miR-126 is associated with 
significantly prolonged disease-free survival 
and overall survival (51). Furthermore, an 
increased miR-501-5p, miR-23b-3p (2, 28), 
miR-21 (52), miR-125b (53) and a decreased 
miR-126 (52) are indicators of worse 
outcome in metastatic patients. Other 
studies report that the high miR-21/10b 
ratio is associated with a poor prognosis in 
non-metastatic ccRCC patients (54). 
Recently, it has been published that the 
differential expression of miR-30c, miR-451 
and miR-126 are associated with overall 
survival in ccRCC patients (55). A miR 
signature that includes the upregulation of 
miR-21-5p, 142-3p, let-7g-5p, let- 7i-5p and 
424-5p, as well as the downregulation of 
miR-204-5p is associated with high stage, 
grade and progression of ccRCC (56). 
Another miRNA signature consisting of 22 
miRNAs that are significantly linked to 
patient survival in ccRCC was recently 
identified (57).  Finally, it has also been 
reported that the expression some miRs may 
predict site of metastasis. For example, the 
decreased expression of miR-10b is 
associated with brain metastasis, while the 
upregulation of miR-199b and the 
downregulation of miR-615 are linked to 
lung metastasis in patients with advanced 
ccRCC (55).  
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MicroRNAs and drug resistance 
 
In addition to their role in tumor 
progression, miRs could also affect response 
to therapy. The downregulation of miR-200c 
in RCC causes increased expression of the 
CYP1B1 gene resulting in pharmacological 
resistance to docetaxel treatment (58). 
Moreover, the upregulation of miR-200c 
enhanced the sensitivity of ccRCC cells to 
sorafenib or imatinib, inhibiting cell 
proliferation by targeting heme oxygenase-1 
(HO-1) mRNA (59). The upregulation of miR-
942, miR-133a, miR-628-5p, and miR-484 
was associated with sunitinib resistance in 
metastatic RCC patients. In particular, the 
increased expression of miR-942 alone 
could accurately predict sunitinib 
resistance that occurs by MMP-9 
upregulation and VEGF secretion (60). 
Other studies show that miR-141 
downregulation drives epithelial-to-
mesenchymal transition (EMT) in ccRCC 
and is associated with an unfavorable 
response to sunitinib treatment. In vitro 
reintroduction of miR-141 reversed EMT 
and decreased cell viability in hypoxic 
conditions (61). To date, about 28 miRNAs 
related to poor response and 23 associated 
with prolonged response to sunitinib 
treatment have been identified (62).  
 
MicroRNAs for gene therapy  
 
As previously discussed, miRs may act as 
oncogenes or onco-suppressors, 
contributing to development, growth and 
metastasis of RCC. Therefore, the restoring 
of normal levels of onco-suppressor miRs or 
the degradation of onco-miRs by using 
specific anti-miR sequences could be an 
attractive therapeutic strategy for the 
treatment of metastatic ccRCC. In this 
regard, the downregulation of the miR-200 
family in different tumors is associated with 
cell migration, invasion, and metastasis by 
the increased expression of IL-8 and CXCL1 
genes that promote angiogenesis. The 
delivery of miR-200 members into the tumor 
endothelium of orthotopic cancer models by 
using specific nanoparticle resulted in 
marked reduction of metastasis and 
angiogenesis (63). The downregulation of 
miR-99a in RCC tissues was associated with 
distant metastases and poor prognosis in 
RCC patients through the activation of the 
mTOR pathway. The restoration of miR-99a 
levels in RCC cells inhibited cell growth, 
migration and invasion. Moreover, intra-
tumoral delivery of miR-99a reduced tumor 
growth in murine xenograft models of 
human RCC (64). The development of 
specific miR-targeted therapies, such as the 
reintroduction of onco-suppressor miRNAs 
or the inhibition of onco-miRs in RCC cells, 
could have significant translational 
implications such as improvement of the 
clinical picture, management and quality of 
life of RCC patients. However, there are 
several obstacles to deliver miRs/anti-miRs 
into the tumor cell including low cellular 
uptake, endosomal escape, 
immunogenicity, degradation in the 
bloodstream, and rapid renal clearance. 
Moreover, for a successful miR-based 
therapy, specific delivery of miR molecules 
to target the organ is important. There is an 
urgent need for developing efficient 
transfection methods as well as target-
specific delivery systems to realize the full 
therapeutic potential of miRs (65). 
 
Conclusions 
 
This review gives an overview of the impact 
of miRs in renal tumorigenesis, their 
potential role as biomarkers and therapeutic 
targets. MiRs show a relative versatility of 
use, however they may also show some 
practical disadvantages largely because of 
problems associated with accurate 
quantification in biological fluids. In fact, 
miRNA analysis in paraffin embedded 
tissues as well as in serum or in other 
biological fluids may be complicated by the 
absence of specific methods of 
standardization and suitable cut-off values. 
Furthermore, miR expression could be 
affected by genetic factors, environment, 
lifestyle and by sample collection methods. 
Despite these potential limitations, a large 
number of studies showing miRs as 
predictive biomarkers in different cancer 
types are emerging. Further studies using 
large independent cohorts of ccRCC patients 
are needed to validate miRs as biomarkers 
that are useful in clinical practice. The 
combination of miRs and other renal cancer 
biomarkers such as VEGF and VEGF-
related proteins, cytokines and lactate 
dehydrogenase (66) could improve the 
reliability of these putative biomarkers. 
Therefore, miRs could become a powerful 
tool for clinical management of high grade 
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and metastatic ccRCC patients, opening 
new horizons to achieve personalized 
medicine. 
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